What is the current Price Target for the Petros Pharmaceuticals Inc stock?

The average Petros Pharmaceuticals Inc target price is $1.00. This is 171.74% higher than the current stock price. 1 Analyst has issued a Petros Pharmaceuticals Inc price target 2025.

How high will the Petros Pharmaceuticals Inc stock rise?

No reliable answer can be given as to how high the Petros Pharmaceuticals Inc stock will rise. The performance of stocks, including the Petros Pharmaceuticals Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Petros Pharmaceuticals Inc stock today?

The performance of Petros Pharmaceuticals Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Petros Pharmaceuticals Inc stock fall?

The decline in Petros Pharmaceuticals Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Petros Pharmaceuticals Inc Forecast, price target & analysts

$0.37

4.87% today

Nasdaq, Dec 30, 09:50 pm CET

ISIN

US71678J1007

Symbol

PTPI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Petros Pharmaceuticals Inc Target price 2024 - Analyst rating & recommendation

Petros Pharmaceuticals Inc Classifications & Recommendation:

Buy

100%

Petros Pharmaceuticals Inc Price Target

Target Price	$1.00
Price	$0.37
Potential	171.74% register free of charge
Number of Estimates	1

	1 Analyst has issued a Petros Pharmaceuticals Inc price target 2025. The average Petros Pharmaceuticals Inc target price is $1.00. This is 171.74% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 1 Analysts recommend Petros Pharmaceuticals Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Petros Pharmaceuticals Inc stock has an average upside potential 2025 of 171.74% register free of charge . Most analysts recommend the Petros Pharmaceuticals Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '23	2024 Estimates
EV/Sales		0.81

Based on analysts' sales estimates for 2024, the Petros Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

Unlock

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of

Unlock

This results in the following potential growth metrics and future valuations:

Current	0.69	183.13%
2024	0.81 17.88% Unlock
2025	0.81 0.75% Unlock

Current	0.50	3.54%
2024	0.58 14.54% Unlock
2025	0.57 0.75% Unlock

Petros Pharmaceuticals Inc...

Discover more stocks with a high price target

Valneva 268.86%

CureVac N.V. 117.96%

Moderna 81.31%

Bavarian Nordic 59.49%

Teamviewer 56.15%

RWE 47.84%

Nel ASA 47.09%

Alibaba Group Holding Ltd 43.74%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now